Angiotensin Receptor Blockers (ARBs) Market Report 2026

The angiotensin receptor blockers (arbs) market size has grown steadily in recent years. It will grow from $8.78 billion in 2025 to $9.18 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to rising prevalence of hypertension, growing awareness of cardiovascular diseases, expansion of hospital networks, introduction of new arb molecules, increasing research in kidney disease treatments.

The angiotensin receptor blockers (arbs) market size is expected to see steady growth in the next few years. It will grow to $11.02 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to aging population, growing demand for personalized medicine, technological advancements in drug delivery systems, increase in healthcare expenditure, expansion of specialty clinics. Major trends in the forecast period include personalized hypertension management, growth in chronic kidney disease treatments, expansion of cardiovascular disease therapies, increasing adoption of oral arb formulations, rise in hospital & specialty clinic prescriptions.

The growing incidence of cardiovascular diseases is expected to drive the growth of the angiotensin receptor blockers market in the coming years. Cardiovascular disease (CVD) refers to any condition that affects the heart or blood vessels and is often linked to the buildup of fatty deposits in the arteries (atherosclerosis) and a higher risk of blood clots. Angiotensin receptor blockers help lower blood pressure and enhance the heart’s ability to pump blood by promoting relaxation of veins and arteries, thereby reducing the risk of cardiovascular disease. For example, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, representing a 4% increase from 224.4 per 100,000 in 2023. Therefore, the rising incidence of cardiovascular diseases is contributing to the growth of the angiotensin receptor blockers market.

The rising prevalence of hypertension is expected to drive the growth of the angiotensin receptor blockers (ARBs) market in the coming years. Hypertension, commonly referred to as high blood pressure, is a condition characterized by persistently elevated pressure in the blood vessels. Angiotensin receptor blockers (ARBs) are widely used medications for the treatment of hypertension and primarily work by relaxing and widening blood vessels, allowing blood to flow more easily. As the number of individuals affected by hypertension increases, the demand for angiotensin receptor blockers is expected to rise accordingly. For example, in March 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported that approximately 1.28 billion adults aged 30 to 79 worldwide have hypertension, with nearly two-thirds living in low- and middle-income countries. It is also estimated that 46% of adults with hypertension are unaware of their condition. Therefore, the growing prevalence of hypertension is driving the expansion of the angiotensin receptor blockers (ARBs) market.

Major companies in the angiotensin receptor blocker market are focusing on developing advanced products, such as angiotensin receptor neprilysin inhibitors, to expand treatment options and improve outcomes for patients with cardiovascular diseases. Angiotensin receptor neprilysin inhibitors (ARNIs) are a class of drugs used in the management of heart failure. For example, in January 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical company, launched sacubitril and valsartan tablets for the treatment of heart failure, specifically targeting heart failure with reduced ejection fraction (HFrEF). This combination belongs to the ARNI class of medications. Sacubitril enhances the natriuretic peptide system, helping to reduce fluid overload and promote blood vessel dilation, while valsartan inhibits the renin-angiotensin system to lower blood pressure and reduce cardiac workload. Together, they improve heart failure symptoms, lower the risk of cardiovascular mortality, and reduce hospitalizations related to heart failure. The product is marketed under the brand name Sacu V.

Major companies operating in the angiotensin receptor blockers (arbs) market are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, AbbVie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma, Thermo Fisher Scientific.

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2025. The regions covered in the angiotensin receptor blockers (arbs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the angiotensin receptor blockers (arbs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the angiotensin receptor blockers (ARBs) market by increasing import costs for raw materials and active pharmaceutical ingredients, thereby affecting production costs. The segments most affected include high-demand products like valsartan and losartan, with Asia-Pacific regions such as India and China experiencing notable disruptions. While tariffs have slowed some market expansion, they have also incentivized local manufacturing and sourcing strategies, potentially improving regional self-sufficiency and cost optimization in the long term.

The angiotensin receptor blockers (arbs) market research report is one of a series of new reports that provides angiotensin receptor blockers (arbs) market statistics, including angiotensin receptor blockers (arbs) industry global market size, regional shares, competitors with a angiotensin receptor blockers (arbs) market share, detailed angiotensin receptor blockers (arbs) market segments, market trends and opportunities, and any further data you may need to thrive in the angiotensin receptor blockers (arbs) industry. This angiotensin receptor blockers (arbs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Angiotensin receptor blockers (ARBs) are medications that relax and widen blood vessels and are used to treat conditions such as high blood pressure (hypertension), heart failure, and kidney disease in individuals with diabetes. Angiotensin is a chemical in the body that causes blood vessels to narrow, which can increase blood pressure and force the heart to work harder.

The key products in the angiotensin receptor blockers (ARBs) category include valsartan, losartan, irbesartan, azilsartan, and olmesartan. Losartan is an angiotensin receptor blocker that helps reduce the risk of stroke while managing hypertension and diabetic nephropathy. These drugs are applied across various conditions, including hypertension, cardiovascular diseases, kidney diseases, and others, and are used by end-users such as hospitals, specialty clinics, and ambulatory surgical centers.

The angiotensin receptor blockers (ARBs) market consists of sales of candesartan and eprosartan. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.